OTCMKTS:GNHAF - Vifor Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$125.38
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Vifor Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNHAF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNHAF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Vifor Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $125.38.
Hold
The current consensus among 6 investment analysts is to hold stock in Vifor Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/28/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
10/22/2020Credit Suisse GroupReiterated RatingOutperform
i
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
10/21/2020UBS GroupReiterated RatingNeutral
i
9/4/2020Stifel NicolausReiterated RatingBuy
i
9/2/2020BarclaysReiterated RatingEqual Weight
i
8/26/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
8/13/2020UBS GroupReiterated RatingNeutral
i
8/12/2020Credit Suisse GroupReiterated RatingOutperform
i
4/16/2020UBS GroupUpgradeSell ➝ Neutral
i
(Data available from 11/28/2015 forward)
Vifor Pharma logo
Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used in the intravenous treatment of iron deficiency; Mircera, a long-acting erythropoiesis-stimulating agent to treat symptomatic anaemia associated with the chronic kidney disease (CKD); Venofer, a solution for iron sucrose used in the intravenous treatment of iron deficiency; and Invokana to treat diabetic kidney disease. It provides Retacrit to treat anaemia due to CKD; Velphoro, a non-calcium, iron-based, and chewable phosphate binder to control the phosphate levels in the blood of adults with CKD; and Veltassa, a sodium-free potassium binder to treat hyperkalaemia in adult patients. The company offers Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman; Broncho-Vaxom, to treat recurrent respiratory infections; Uro-Vaxom to treat recurrent urinary tract infections; Doxium, an oral treatment for diabetic retinopathy and haemorrhoidal syndrome; and Uro-Vaxom to treat recurrent urinary tract infections. It provides Rayaldee, which is in pre commercial stage to treat secondary hyperparathyroidism in patients with CKD; Avacopan, which is in pre commercial stage to treat orphan and rare renal diseases; Vadadustat, which is Phase III clinical trials to treat anaemia due to CKD; CR845, which is in Phase III clinical trials to treat CKD disease-associated pruritus; CCX140, which is in Phase II clinical trials to treat patients with focal segmental glomerulosclerosis; and VIT-2763, which is in Phase II clinical trial to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.
Read More

Today's Range

Now: $125.38
$125.38
$125.38

50 Day Range

MA: $128.84
$125.38
$132.53

52 Week Range

Now: $125.38
$106.18
$193.15

Volume

N/A

Average Volume

200 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A